{"id":85567,"date":"2026-06-16T20:27:26","date_gmt":"2026-06-16T20:27:26","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/85567\/"},"modified":"2026-06-16T20:27:26","modified_gmt":"2026-06-16T20:27:26","slug":"companion-diagnostics-market-to-reach-usd-3-6-bn-by-2036-as-roche","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/85567\/","title":{"rendered":"Companion Diagnostics Market to Reach USD 3.6 Bn by 2036 as Roche,"},"content":{"rendered":"

\"Companion<\/a><\/p>\n

Companion Diagnostics Market<\/p>\n

The global companion diagnostics market size was valued at USD 1.2 Bn in 2025 and is projected to reach USD 3.6 Bn by 2036, expanding at a CAGR of 10.4% from 2026 to 2036. The market growth is driven by innovations in genomic and molecular testing technologies and the growing need for targeted therapies in oncology.<\/p>\n

\ud83d\udc49 Get sample market research report copy today@ https:\/\/www.transparencymarketresearch.com\/sample\/sample.php?flag=S&rep_id=387 <\/p>\n

Market Overview<\/p>\n

Companion diagnostics refer to medical devices or tests that aim to improve the effectiveness of certain therapeutic drugs through the discovery of patients who are most likely to respond positively to a particular course of treatment. These diagnostics play a vital role in the personalized medicine era, where treatments are customized based on individual patient characteristics instead of the conventional approach, where everyone gets the same treatment. Essentially, the main purpose of companion diagnostics is to scrutinize biomarkers – be they proteomic, genetic, or other molecular patterns that help predict the patients’ response to a specific drug.<\/p>\n

The importance of companion diagnostics is most visible in oncology, where they help in choosing the most appropriate targeted therapies. The tests that find specific genetic mutations in cancer cells can help oncologists to prescribe drugs that have a higher probability of achieving the desired effects in patients. Apart from improving the effectiveness of treatments, this also reduces the risk of side effects caused by the use of drugs that are not effective.<\/p>\n

Analysts’ Viewpoint<\/p>\n

The companion diagnostics market is experiencing substantial growth, primarily driven by the widespread adoption of personalized medicine and tailored treatment approaches. Companion diagnostics are basically the healthcare providers’ most important tools in figuring out which patients will benefit the most from a certain therapeutic drug, thus not only increasing the treatment efficacy but also minimizing the side effects. As cancer is the major focus of this sector, with biomarkers playing an increasingly important role in patient stratification, the demand for companion diagnostics is projected to go up.<\/p>\n

In addition, the development of genomic technologies and the growing number of targeted therapies are driving the market growth, with many pharmaceutical companies partnering in the creation of companion diagnostics along with their drugs. Moreover, regulatory support, especially from the FDA and EMA, is a significant factor in market boosting, as these agencies grant diagnostic devices that go hand in hand with new therapeutics considerably faster market access.<\/p>\n

Analysis of Key Players<\/p>\n

Strong investments in molecular diagnostic technologies, biomarker development, and strategic collaborations with pharmaceutical firms characterize the competitive landscape.<\/p>\n

Leading companies operating in the global companion diagnostics market include:<\/p>\n

\u2022 Roche Diagnostics

\n\u2022 Thermo Fisher Scientific

\n\u2022 Agilent Technologies

\n\u2022 Abbott Laboratories

\n\u2022 QIAGEN

\n\u2022 BioMe\u0301rieux

\n\u2022 Danaher Corporation

\n\u2022 Illumina Inc.

\n\u2022 Siemens Healthineers

\n\u2022 Myriad Genetics

\n\u2022 Guardant Health

\n\u2022 Foundation Medicine

\n\u2022 Bio-Rad Laboratories

\n\u2022 Exact Sciences Corporation

\n\u2022 NeoGenomics Laboratories

\n\u2022 Invivoscribe

\n\u2022 Sysmex Corporation

\n\u2022 F. Hoffmann-La Roche Ltd.

\n\u2022 ArcherDX

\n\u2022 Other Prominent Players<\/p>\n

Strategic partnerships between pharmaceutical and diagnostic companies remain a major industry trend. Several market participants are actively focusing on co-development agreements to improve patient stratification and enhance treatment efficacy.<\/p>\n

Recent Developments (2025-2026)<\/p>\n

\u2022 In February 2026, Roche Diagnostics announced expansion of its oncology companion diagnostic portfolio with advanced genomic profiling solutions aimed at improving precision oncology outcomes.<\/p>\n

\u2022 In October 2025, Thermo Fisher Scientific strengthened its molecular diagnostics capabilities through expanded partnerships with biopharmaceutical companies for companion diagnostic development.<\/p>\n

\u2022 In June 2025, QIAGEN launched new biomarker testing solutions to support precision medicine and targeted cancer therapies.<\/p>\n

\u2022 In March 2025, Illumina expanded its next-generation sequencing applications to accelerate companion diagnostic development for oncology and rare diseases.<\/p>\n

\ud83d\udc49 Discuss Implications for Your Industry Request Sample Research Report PDF@ https:\/\/www.transparencymarketresearch.com\/sample\/sample.php?flag=B&rep_id=387 <\/p>\n

Challenges<\/p>\n

\u2022 High Development Costs: Companion diagnostic development requires substantial R&D investments and regulatory approvals.<\/p>\n

\u2022 Complex Regulatory Pathways: Co-approval requirements for drugs and diagnostics can delay commercialization timelines.<\/p>\n

\u2022 Limited Reimbursement: In several healthcare systems, reimbursement challenges limit diagnostic accessibility.<\/p>\n

\u2022 Biomarker Validation Issues: Ensuring biomarker reliability and clinical relevance remains a significant hurdle.<\/p>\n

Opportunities<\/p>\n

\u2022 Cancer Diagnostics Expansion: Rising incidence of cancer creates strong demand for biomarker-driven testing.<\/p>\n

\u2022 Rare Disease Applications: Companion diagnostics present significant opportunities in genetic and orphan diseases.<\/p>\n

\u2022 Liquid Biopsy Growth: Increasing adoption of minimally invasive liquid biopsy testing offers strong market potential.<\/p>\n

\u2022 Emerging Markets: Expanding healthcare infrastructure in developing economies supports market penetration.<\/p>\n

Market Segmentation<\/p>\n

\u27a4 By Technology<\/p>\n

\u2022 Polymerase Chain Reaction (PCR)

\n\u2022 Next-Generation Sequencing (NGS) (Fastest Growing Segment)

\n\u2022 Immunohistochemistry (IHC)

\n\u2022 In Situ Hybridization (ISH)

\n\u2022 Others<\/p>\n

\u27a4 By Indication<\/p>\n

\u2022 Oncology (Leading Segment)

\n\u2022 Neurological Disorders

\n\u2022 Infectious Diseases

\n\u2022 Cardiovascular Diseases

\n\u2022 Rare Genetic Disorders<\/p>\n

\u27a4 By End-user<\/p>\n

\u2022 Hospitals & Diagnostic Laboratories

\n\u2022 Pharmaceutical & Biopharmaceutical Companies

\n\u2022 Research Institutes<\/p>\n

\u27a4 By Region<\/p>\n

\u2022 North America (Leading Region – 37.2% Market Share in 2025)

\n\u2022 Europe

\n\u2022 Asia Pacific (Fastest Growing Region)

\n\u2022 Latin America

\n\u2022 Middle East & Africa<\/p>\n

Conclusion<\/p>\n

The companion diagnostics market is emerging as a foundational pillar of precision medicine and personalized healthcare. As pharmaceutical companies increasingly focus on targeted therapies, companion diagnostics will become essential for improving treatment efficacy and patient outcomes. Through 2036, advancements in genomic technologies, biomarker discovery, and AI-driven diagnostics are expected to redefine disease management and accelerate market expansion globally.<\/p>\n

\ud83d\udc49 To buy this comprehensive market research report, click here to inquire@ https:\/\/www.transparencymarketresearch.com\/checkout.php?rep_id=387<\/p>\n

Frequently Asked Questions<\/p>\n

\u2022\tHow big was the global companion diagnostics market in 2025?<\/p>\n

The global companion diagnostics market was valued at US$ 1.2 Bn in 2025<\/p>\n

\u2022\tWhat is the projected size of the companion diagnostics Industry by 2036?<\/p>\n

The global companion diagnostics Industry is projected to cross US$ 3.6 Bn by the end of 2036<\/p>\n

\u2022\tWhat are the factors driving the companion diagnostics market?<\/p>\n

Innovations in genomic and molecular testing technologies and growing need for targeted therapies in oncology<\/p>\n

\u2022\tWhat is the companion diagnostics market expected to grow during the forecast period?<\/p>\n

The global companion diagnostics market is anticipated to grow at a CAGR of 10.4% from 2026 to 2036<\/p>\n

\u2022\tWhich region is expected to dominate the companion diagnostics market during the forecast period?<\/p>\n

North America is expected to account for the largest share from 2026 to 2036<\/p>\n

Explore Latest Research Reports by Transparency Market Research: <\/p>\n

Flow Chemistry Market – https:\/\/www.transparencymarketresearch.com\/flow-chemistry-market.html <\/p>\n

Data Center Infrastructure Management Market – https:\/\/www.transparencymarketresearch.com\/data-center-infrastructure-management-market.html <\/p>\n

Building Automation and Control System Market – https:\/\/www.transparencymarketresearch.com\/building-automation-control-system-market.html<\/p>\n

About Transparency Market Research<\/p>\n

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.<\/p>\n

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.<\/p>\n

Contact:<\/p>\n

Abhishek Budholiya

\nTransparency Market Research Inc.

\nState Tower, 90 State Street, Suite 700,

\nAlbany, NY – 12207, United States

\nTel: +1-518-618-1030

\nUSA – Canada Toll Free: 866-552-3453

\nWebsite: https:\/\/www.transparencymarketresearch.com

\nSales Inquiries: sales@transparencymarketresearch.com

\nMedia Inquiries: media@transparencymarketresearch.com<\/p>\n

This release was published on openPR.
\n <\/p>\n","protected":false},"excerpt":{"rendered":"Companion Diagnostics Market The global companion diagnostics market size was valued at USD 1.2 Bn in 2025 and…\n","protected":false},"author":2,"featured_media":85568,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[147,146,142,140,145,149,148,150,139,143,141,144,134],"class_list":["post-85567","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-advertising","tag-marketing","tag-media-release","tag-news-release","tag-pr","tag-pr-marketing","tag-pr-service","tag-pr-strategy","tag-presses-release","tag-pressreleases","tag-public-relations","tag-publicity","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116761673671129857","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=85567"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/85568"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=85567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=85567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=85567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}